Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Q4 2024 Earnings Call Transcript March 6, 2025 CytomX Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.22, ...

Shares of Regeneron Pharmaceuticals Inc. REGN rose 1.30% to $707.51 Friday, on what proved to be an all-around positive ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average rating of “Moderate Buy” from the ...

First Watch Restaurant Group, Inc. (NASDAQ:FWRG – Get Free Report) has earned an average rating of “Moderate Buy” from the ...

Regeneron’s (REGN) treatment of lipodystrophy, mibavademab, was granted FDA orphan designation, according to a post on the agency’s ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase ...

This was the stock's second consecutive day of gains.

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of ...